Although a robust body of work supports SGLT2i use in earlier stages of metabolic dysfunction, associated steatotic liver disease (MASLD), with reported reductions in liver stiffness, hepatic enzymes and visceral adiposity, along with improved insulin sensitivity and a potential slowdown in progression to cirrhosis, evidence in advanced disease remains limited [50,53,54,55,56]. Here, INS is linked to Cirrhosis.